Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of oral PHA-022121 for prophylaxis of hereditary angioedema attacks
MOH_2022-05-04_010778Phase 2Not yet recruiting
- Sponsor
- Pharvaris
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucrictibant in hereditary angioedema (HAE) (3 arms), sponsored by Pharvaris. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2022-05-04_010778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-04_010778.